Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study

BACKGROUND: This study aimed to compare the efficacy of abiraterone acetate (AA) versus docetaxel (T) as first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) patients with or without the ineligible factors of the COU-AA-302 study (presence of visceral metastase...

Descripción completa

Detalles Bibliográficos
Autores principales: Poon, Darren M.C., Chan, Kuen, Lee, Siu H., Chan, Tim W., Sze, Henry, Lee, Eric K.C., Lam, Daisy, Chan, Michelle F.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857184/
https://www.ncbi.nlm.nih.gov/pubmed/29556486
http://dx.doi.org/10.1016/j.prnil.2017.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857184/
https://www.ncbi.nlm.nih.gov/pubmed/29556486
http://dx.doi.org/10.1016/j.prnil.2017.08.001

Ejemplares similares